EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieÜbersichtsarbeit

Comparison of safety and efficacy of femoropopliteal arterial disease using different dose drug-coated balloons: Systematic review and meta-analysis

Carlos A Núñez-Castellanos iD, María F Esquinca-Morales, Meritxell C Beristain-Bolaños iD, Daniela I De León Avecilla, Jorge S Aguirre-Ocaña iD, Osiris Y Diaz-De-La-Cruz, Javier E Anaya-Ayala, Carlos A Hinojosa iD

Vascular · 2026

DOI: 10.1177/17085381241307765 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Vascular, 2026. Verfasst von Carlos A Núñez-Castellanos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Human Medicine, Universidad Autonoma de Chiapas, Tuxtla Gutiérrez, Mexico. Hauptthemen laut MEDLINE: Femoral Artery, Popliteal Artery, Peripheral Arterial Disease, Coated Materials, Biocompatible. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Endovascular therapy with balloon percutaneous angioplasty (PTA) in the femoro-popliteal segment is frequently performed, however, long-term favorable outcomes and patency remain challenging, with restenosis rates reaching 60% post-standard balloon angioplasty. Drug-coated balloons (DCBs) have shown promise in improving these outcomes; Paclitaxel, used in DCBs, inhibits hyperplasia and smooth muscle cell proliferation, reducing restenosis; however, the optimal dose of Paclitaxel remains unclear, with high-dose (HD-DCB [>3 mg/mm 2 ]) and low-dose (LD-DCB [

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Femoral ArteryPopliteal ArteryPeripheral Arterial DiseaseCoated Materials, BiocompatibleAngioplasty, BalloonVascular Access DevicesCardiovascular AgentsPaclitaxelHumansVascular PatencyTime FactorsRisk FactorsTreatment OutcomeMaleLimb SalvageFemaleAgedMiddle AgedEquipment DesignRisk AssessmentAmputation, Surgical

Stichwörter der Autor:innen

Femoropopliteal diseasedrug-coated balloonsendovascular interventionshigh-doselow-dose

Substanzen

Coated Materials, BiocompatibleCardiovascular AgentsPaclitaxel

Autor:innen und Institutionen

  • Faculty of Human Medicine, Universidad Autonoma de Chiapas, Tuxtla Gutiérrez, Mexico.
  • Faculty of Human Medicine, Universidad Popular Autonoma del Estado de Puebla, Puebla, Mexico.
  • Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.
  • Health Center with Expanded Services, Jiquipilas, Chiapas, Mexico.
  • Department of Surgery, Section of Vascular Surgery and Endovascular Therapy, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

ORCID-Profile: Carlos A Núñez-Castellanos, Meritxell C Beristain-Bolaños, Jorge S Aguirre-Ocaña, Carlos A Hinojosa

Zitieren

APA

Núñez-Castellanos, C. A., Esquinca-Morales, M. F., Beristain-Bolaños, M. C., De León Avecilla, D. I., Aguirre-Ocaña, J. S., Diaz-De-La-Cruz, O. Y., Anaya-Ayala, J. E., & Hinojosa, C. A. (2026). Comparison of safety and efficacy of femoropopliteal arterial disease using different dose drug-coated balloons: Systematic review and meta-analysis. Vascular. https://doi.org/10.1177/17085381241307765

Vancouver

Núñez-Castellanos CA, Esquinca-Morales MF, Beristain-Bolaños MC, De León Avecilla DI, Aguirre-Ocaña JS, Diaz-De-La-Cruz OY, et al. Comparison of safety and efficacy of femoropopliteal arterial disease using different dose drug-coated balloons: Systematic review and meta-analysis. Vascular. 2026. doi:10.1177/17085381241307765

BibTeX
@article{NezCastellanos2026,
  author = {Núñez-Castellanos, Carlos A and Esquinca-Morales, María F and Beristain-Bolaños, Meritxell C and De León Avecilla, Daniela I and Aguirre-Ocaña, Jorge S and Diaz-De-La-Cruz, Osiris Y and Anaya-Ayala, Javier E and Hinojosa, Carlos A},
  title = {Comparison of safety and efficacy of femoropopliteal arterial disease using different dose drug-coated balloons: Systematic review and meta-analysis},
  journal = {Vascular},
  year = {2026},
  doi = {10.1177/17085381241307765}
}
Kostenlos starten →